Advertisement

International Journal of Clinical Oncology

, Volume 18, Issue 5, pp 839–846 | Cite as

Performance status of patients is the major prognostic factor at all stages of pancreatic cancer

  • Faruk Tas
  • Fatma Sen
  • Hatice Odabas
  • Leyla Kılıc
  • Serkan Keskın
  • Ibrahım Yıldız
Original Article

Abstract

Background

The aim of this study was to identify and evaluate the clinicopathologic factors and to elucidate the clinical importance of performance status on the outcome of patients with pancreatic cancer.

Materials and method

The data of 335 patients with histologically confirmed diagnosis of pancreatic cancer who were treated and followed up between 2000 and 2010 were recorded from medical charts.

Results

The median age of the patients was 59 years (range 25–88 years) and 226 (67.5 %) were male. The study group comprised localized disease (18 %), locally advanced disease (36 %) and metastatic disease (46 %). The median survival of all patients was 280 days and the 4-year survival rate was 5 %. Univariate analysis indicated that initial poor performance status of patients (PS 2–4) was significantly associated with shorter survival in localized (p = 0.015), locally advanced (p = 0.01), metastatic stage (p < 0.001) and in the whole group (p < 0.001). Multivariate analyses also showed the same findings except in local disease (p = 0.04 for locally advanced disease, p = 0.002 for metastatic stage, and p < 0.001 for all stages). In patients with poor performance status, severe weight loss (>10 %) (p = 0.007), large tumor diameter (>3 cm) (p = 0.046), and especially metastatic disease (p < 0.001) were associated with significantly shorter overall survival.

Conclusions

The performance status of a patient is the major prognostic factor predicting overall survival for all stages of pancreatic cancer. Severe weight loss, large tumor, and metastatic disease were found to be unfavorable prognostic factors in patients with poor performance status.

Keywords

Pancreatic cancer Performance status Prognosis Survival 

Notes

Conflict of interest

None.

References

  1. 1.
    Sener SF, Fremgen A, Menck HR et al (1999) Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 189:1–7CrossRefPubMedGoogle Scholar
  2. 2.
    Yeo CJ, Cameron JL, Sohn TA et al (1997) Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 226:248–255CrossRefPubMedGoogle Scholar
  3. 3.
    Sperti C, Pasquali C, Piccoli A et al (1996) Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 83:625–631CrossRefPubMedGoogle Scholar
  4. 4.
    Klaassen DJ, MacIntyre JM, Catton GE et al (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 3:373–378PubMedGoogle Scholar
  5. 5.
    Chauffert B, Mornex F, Bonnetain F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 19:1592–1599CrossRefPubMedGoogle Scholar
  6. 6.
    Link KH, Gansauge F, Görich J et al (1997) Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur J Surg Oncol 23:409–414CrossRefPubMedGoogle Scholar
  7. 7.
    Papadoniou N, Kosmas C, Gennatas K et al (2008) Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res 28:543–549PubMedGoogle Scholar
  8. 8.
    Tas F, Aykan F, Alici S et al (2001) Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 24:547–550CrossRefPubMedGoogle Scholar
  9. 9.
    Krishnan S, Rana V, Janjan NA et al (2006) Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107:2589–2596CrossRefPubMedGoogle Scholar
  10. 10.
    Ozaki H, Hiraoka T, Mizumoto R et al (1999) The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 29:16–22CrossRefPubMedGoogle Scholar
  11. 11.
    Micke O, Bruns F, Schäfer U et al (2003) CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 23:835–840PubMedGoogle Scholar
  12. 12.
    Ziske C, Schlie C, Gorschlüter M et al (2003) Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89:1413–1417CrossRefPubMedGoogle Scholar
  13. 13.
    Hess V, Glimelius B, Grawe P et al (2008) CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 9:132–138CrossRefPubMedGoogle Scholar
  14. 14.
    Takeuchi M, Kondo S, Sugiura H et al (1998) Pre-operative predictors of short-term survival after pancreatic cancer resection. Hepatogastroenterology 45:2399–2403PubMedGoogle Scholar
  15. 15.
    Cady B, Jenkins RL, Steele GD Jr et al (1998) Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 227:566–571CrossRefPubMedGoogle Scholar
  16. 16.
    Sobin LH, Wittekind Ch (eds) (1997) UICC TNM classification of malignant tumors, 5th edn. Wiley, New YorkGoogle Scholar
  17. 17.
    Schneider G, Siveke JT, Eckel F et al (2005) Pancreatic cancer: basic and clinical aspects. Gastroenterology 128:1606–1625CrossRefPubMedGoogle Scholar
  18. 18.
    Weber A, Kehl V, Mittermeyer T et al (2010) Prognostic factors for survival in patients with unresectable pancreatic cancer. Pancreas 39:1247–1253CrossRefPubMedGoogle Scholar
  19. 19.
    Ikeda M, Okada S, Tokuuye K et al (2001) Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91:490–495CrossRefPubMedGoogle Scholar
  20. 20.
    Ishii H, Okada S, Nose H et al (1996) Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 12:267–271CrossRefPubMedGoogle Scholar
  21. 21.
    Engelken FJ, Bettschart V, Rahman MQ et al (2003) Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 29:368–373CrossRefPubMedGoogle Scholar
  22. 22.
    Heinemann V, Quietzsch D, Gieseler F et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946–3952CrossRefPubMedGoogle Scholar
  23. 23.
    Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516CrossRefPubMedGoogle Scholar
  24. 24.
    Van Cutsem E, van de Velde H, Karasek P et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438CrossRefPubMedGoogle Scholar
  25. 25.
    Storniolo AM, Enas NH, Brown CA et al (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85:1261–1268CrossRefPubMedGoogle Scholar
  26. 26.
    Riess H, Helm A, Niedergethmann M et al (2005) A randomized, prospective, multicenter phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs gemcitabine alone in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 23:4009Google Scholar

Copyright information

© Japan Society of Clinical Oncology 2012

Authors and Affiliations

  • Faruk Tas
    • 1
  • Fatma Sen
    • 1
  • Hatice Odabas
    • 1
  • Leyla Kılıc
    • 1
  • Serkan Keskın
    • 1
  • Ibrahım Yıldız
    • 1
  1. 1.Institute of OncologyUniversity of IstanbulIstanbulTurkey

Personalised recommendations